Each year in the U.S., at least 2.8 million people get antibiotic-resistant infections, leading to 35,000 deaths, according to the U.S. CDC. Ancient amber (fossilized tree resin) have been used by humans in Baltic countries for medicinal purposes for centuries. Now, researchers from the University of Minnesota have pinpointed compounds that help explain Baltic amber's therapeutic effects and that could lead to new medicines to combat antibiotic-resistant infections.
The vaccine aims to curb the global spread of gonorrhea and strains of super gonorrhea antibiotic-resistant bacteria.
In this GEN webinar, sponsored by Horizon Discovery, we will present data showing how a new CRISPRsc screening platform from Horizon offers a streamlined approach to elucidating valuable and intriguing biological information critical to resolving complex biological questions.
Canadian officials say the investment demonstrates the government’s commitment to grow domestic manufacturing capacity and to prepare for future pandemics.
Epizyme recently detailed its development strategy and pipeline priorities over the next five years during a “Strategic Vision Call.” Those priorities include launching two signal-finding “basket” studies in the second half of 2021 to evaluate tazemetostat safety and efficacy across multiple new types of blood and solid tumors; and advancing to the clinic its SETD2 inhibitor program.
The past few years have seen several flashy demonstrations of how artificial intelligence (AI) algorithms may transform biomedical research, particularly with respect to drug discovery. AI’s champions in the industry remain wary about overselling the technology’s current capabilities. Nevertheless, a growing number of companies now recognize the value that AI—and more specifically, the subset of algorithmic techniques known as “machine learning”—can deliver at various stages in the drug discovery process.
The collaboration comes as the FDA is reviewing an NDA for infigratinib in patients with previously treated, FGFR-mutant cholangiocarcinoma (bile duct cancer).
Scribe—one of a new wave of gene editing biotech companies—focuses on developing CRISPR-based treatments through its genetic modification platform, designed to build and apply its suite of CRISPR technologies designed for therapeutic use.